血清CA19-9、CEA和CA125对良恶性胰腺疾病的诊断价值

目的探讨血清CA19-9、CEA和CA125对胰腺癌（pancreatic cancer,PC）、慢性胰腺炎（chronic pancreatitis,CP）鉴别诊断的临床价值。方法采用电化学发光免疫分析法检测60例胰腺癌患者（PC组）,60例慢性胰腺炎患者（CP组）和60名健康体检者（对照组）外周血清CA19-9、CEA和CA125的表达水平,分析和比较肿瘤标志物单项和联合检测对胰腺癌的诊断价值。结果 PC组血清CA19-9、CEA和CA125的表达水平均明显高于CP组和对照组（P〈0.01）。CP组和对照组之间CA19-9、CEA和CA125比较差异无统计学意义（P〉0.05）。胰腺癌患者CA19-9、CEA和CA125敏感性分别为82.14%、47.36%、37.4%,特异性分别为53.26%、61.26%、63.15%。联合检测时敏感性、特异性分别为93.84%,95.68%。结论 CA19-9、CEA和CA125联合检测可以提高胰腺癌的诊断价值,有助于更好地鉴别良恶性胰腺疾病。

The diagnostic value of serum CA19-9, CEA and CA125 in patients with the benign and malignant diseases of pancreatic

Objective To investigate the value of serum CA19-9, CEA and CA125 in diagnosing pancreatic cancer（PC） and chronic pancreatitis（CP）. Methods Electrochemiluminescence immunoassay（ECL） was used to detected the peripheral serum levels of CA19-9, CEA and CA125 in 60 patients with pancreatic cancer（PC group）, 60 patients with chronic pancreatitis（CP group） and 60 healthy individuals（control group）. The comparison and analysis are made on the value of serum tumor markers in the diagnosis of pancreatic cancer by application of single and joint assay of CA19-9, CEA and CA125. Results The serum levels of CA19-9, CEA and CA125 in PC group were significantly higher than those in CP group and control group（P〈0.01）. CA19-9, CEA and CA125 were not significantly different between CP group and control group（P〉0.05）. The sensitivities of CA19-9, CEA and CA125 in Patients with pancreatic cancer were 82.14%, 47.36% and 37.4%, while the specificities were 53.26%, 61.26% and 63.15%. The sensitivity and specificity of joint detection of CA19-9, CEA and CA125 were 93.84% and 95.68~/,. Conclusion The joint detection of CA19-9, CEA and CA125 can improve the diagnostic value of pancreatic cancer and may be helpful in the differential diagnosis of pancreatic cancer.